Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryMay202015	Fate Therapeutics Announces Pricing of Public Offering of Common Stock SAN DIEGO , May 20, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced the pricing of an underwritten public offering of Read All »	View HTML Fate Therapeutics Announces Pricing of Public Offering of Common Stock 148.1 KB
Toggle SummaryDec132017	Fate Therapeutics Announces Pricing of Public Offering of Common Stock SAN DIEGO, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the pricing of an underwritten public offering of Read All »	View HTML Fate Therapeutics Announces Pricing of Public Offering of Common Stock 379.7 KB
Toggle SummarySep122019	Fate Therapeutics Announces Pricing of Public Offering of Common Stock SAN DIEGO , Sept. 11, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the pricing Read All »	View HTML
Toggle SummaryMar192024	Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement SAN DIEGO , March 19, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to Read All »	View HTML
Toggle SummaryOct012021	Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting SAN DIEGO , Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that one oral and four poster presentations for the Read All »	View HTML
Toggle SummaryApr222024	Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed / Refractory B-cell Malignancies to be Highlighted Patient Enrollment Initiated in Phase 1 Study of FT819 Read All »	View HTML
Toggle SummaryAug092022	Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8αβ T Cells from TCR-CAR+ Induced Pluripotent Stem Cells TCR - CAR + iPSC-derived CD8αβ T Cells Induced Complete and Durable Responses In Vivo in Systemic Leukemia Model Cell-surface Markers, Gene Transcription Profile, and In Vivo Anti-tumor Activity of TCR - CAR + iPSC-derived CD8αβ T Cells Compared Favorably with Healthy-donor Peripheral Blood CAR T Read All »	View HTML
Toggle SummaryApr282020	Fate Therapeutics Announces Preclinical Data Presentation of Novel CAR MICA/B Cell-based Cancer Immunotherapy Program at the 2020 ASGCT Annual Meeting Program Incorporates New CAR Constructs Designed to Specifically Target the Pan-tumor Associated Stress Proteins MICA and MICB Proprietary Binding Domains Shown to Overcome MICA/B Shedding, a Common Mechanism of Tumor Cell Escape Broadly Observed Across Solid Tumors Exclusive License Agreement with Read All »	View HTML
Toggle SummaryMay162016	Fate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function of Allogeneic Natural Killer Cell Cancer Immunotherapy Adaptive NK Cell Therapy Advancing Toward First-in-Human Clinical Trial in Collaboration with University of Minnesota Program to be Presented Today at Innate Killer Summit 2016 SAN DIEGO, May 16, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated Read All »	View HTML Fate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function of Allogeneic Natural Killer Cell Cancer Immunotherapy 16.4 KB
Toggle SummaryJun112016	Fate Therapeutics Announces Preclinical Data from Immuno-Regulatory CD34+ Cell Therapy for Autoimmune Diseases One-time Administration of Programmed Cells Demonstrates Durable Disease Correction in Type 1 Diabetes Mouse Model ToleraCyte™ Product Candidate Exhibits Enhanced Trafficking to the Pancreas and Potent Regulation of Autoreactive T Cells in Preclinical Testing Preclinical Data Package to Read All »	View HTML Fate Therapeutics Announces Preclinical Data from Immuno-Regulatory CD34+ Cell Therapy for Autoimmune Diseases 384.3 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.